Oxytocic drugs are administered intravenously and intramuscularly to stimulate uterine contractions during labor induction for normal child birth and control bleeding after childbirth. Administration of Oxytocic drugs help in both prevention and treatment of postpartum hemorrhage. Oxytocin also is used to reduce bleeding after childbirth. It also may be used along with other medications or procedures to end a pregnancy. Oxytocin is in a class of medications called oxytocic hormones. It works by stimulating uterine contractions. Oxytocin comes as a solution (liquid) to be given intravenously (into a vein) or intramuscularly (into the muscle) by a doctor or healthcare provider in a hospital or clinic. If oxytocin injection is given to induce labor or to increase contractions, it is usually given intravenously with medical supervision in a hospital. According to the American College of Obstetricians and Gynecologists (ACOG) prophylactic administration of uterotonic agents to prevent uterine atony is recommended. Furthermore, increasing childbirth using labor induction is expected to boost growth of the global oxytocic pharmaceuticals market over the forecast period.

Market Dynamics

The key market players are focusing on adoption of growth strategies such as partnership and acquisitions, to bring in the development of uterine contractility drugs which is attributed to the growth of global oxytocic pharmaceutical market. For instance, in February 2022, Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that it has entered into a sponsored research agreement with Inserm Transfert, the private subsidiary of Inserm, on behalf of Inserm (the French National Institute of Health and Medical Research) and Aix-Marseille Université to study oxytocin in the genetically engineered mouse model of Prader-Willi syndrome, a rare genetic disorder that causes distinct, but related pathological eating disorders in adults and newborns. In adults, Prader-Willi causes hyperphagia, or pathological over-eating, which leads to obesity and other complications associated with significant mortality. In newborns, Prader-Willi causes a deficiency in suckling, which has been shown to be normalized by oxytocin treatment.

Key features of the study:

• This report provides an in-depth analysis of the global oxytocic pharmaceuticals market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

• It profiles key players in the global oxytocic pharmaceuticals market based on the following parameters–Company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Fresenius Kabi AG, Biofutura SpA, Baxter Healthcare Corporation, Pfizer, Inc., Ferring B.V., Novartis AG, Teva Pharmaceuticals Industries Ltd., Abbott Laboratories, AdvaCare Pharma, and EVER Pharma.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global oxytocic pharmaceuticals market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global oxytocic pharmaceuticals market

Detailed Segmentation:

• Global Oxytocic Pharmaceuticals Market, By Indication:
  • Abortion Induced Incomplete
  • Inevitable Abortion
  • Postpartum Hemorrhage
  • Labor Induction
  • Labor Arrest
• Global Oxytocic Pharmaceuticals Market, By Route of Administration:
  • Intramuscular
  • Intravenous Injection/Infusion
• Global Oxytocic Pharmaceuticals Market, By Source of Origin:
  • Synthetic Oxytocin
  • Natural Oxytocin (Animal Pituitary Extract)
• Global Oxytocic Pharmaceuticals Market, By End User:
  • Hospitals
  • Maternity Clinics
• Global Oxytocic Pharmaceuticals Market, By Region:
  • North America
    
    • U.S.
    • Canada
  • Latin America
    
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
  • Fresenius Kabi AG *
  • Biofutura SpA
  • Baxter Healthcare Corporation
  • Pfizer Inc.
  • Ferring B.V.
  • Abbott.
  • Novartis AG
  •  Teva Pharmaceutical Industries Ltd.
  • Abbott
  • AdvaCare Pharma
  • EVER Pharma